

Fusion Protein for Treatment of Inflammatory Diseases

Tech ID: 31812 / UC Case 2016-656-0

ABSTRACT

Researchers at the University of California, Davis have developed a plant-based, fusion protein for use in the treatment of inflammatory diseases.

FULL DESCRIPTION

Inflammatory diseases - such as alpha-1 anti-trypsin deficiency (AATD) and cystic fibrosis (CF) – are currently treated using plasma-derived, IV replacement therapies. Although such therapies are safe and effective, they have limitations due to cost, purity specifications, and limited availability. There is a need for a treatment that avoids the complexity and cost of collection, purification, sterilization, preservation and distribution of plasma.

Researchers at the University of California, Davis have developed a plant-based, elafin-fusion protein that can be used as a potential therapeutic to treat patients with inflammatory diseases. This therapeutic provides a cost-effective and stable treatment option for patients who either lack access to plasma-derived, IV replacement therapies or are seeking a lower cost, alternative therapy. The protein is resistant to proteolytic cleavage and oxidation, and has anti-inflammatory properties. Additionally, the therapeutic exhibits human-like glycosylation, has a longer half-life than other treatments and can be delivered via infusion or inhalation.

APPLICATIONS

- ▶ Protein therapy for inflammatory diseases such as AATD and CF
- ▶ Can be delivered via either infusion or inhalation

FEATURES/BENEFITS

- ▶ Proteolytic cleavage-resistant
- ▶ Oxidation-resistant
- ▶ Improved stability
- ▶ Lower manufacturing and clinical costs compared to current treatment options
- ▶ Extended serum half-life
- ▶ Anti-inflammatory properties
- ▶ Delivery by infusion or inhalation

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	10,918,703	02/16/2021	2016-656

RELATED MATERIALS

CONTACT

Victor Haroldsen

haroldsen@ucdavis.edu

tel: [530-752-7717](tel:530-752-7717).



OTHER INFORMATION

KEYWORDS

Elafin, Fusion proteins, Anti-protease augmentation, Inflammatory disease, Inflammatory lung disease, Inflammatory pulmonary disease, Alpha-1 antitrypsin deficiency, AATD, Cystic fibrosis, Chronic obstructive pulmonary disease, COPD, Plasma-derived IV rep

CATEGORIZED AS

- ▶ **Agriculture & Animal Science**
- ▶ Other
- ▶ **Medical**
- ▶ Disease: Autoimmune and

RELATED CASES

2016-656-0

University of California, Davis
Technology Transfer Office
1 Shields Avenue, Mrak Hall 4th Floor,
Davis,CA 95616

Tel: 530.754.8649
techtransfer@ucdavis.edu
<https://research.ucdavis.edu/technology-transfer/>
Fax: 530.754.7620

© 2019 - 2021, The Regents of the University of California
[Terms of use](#)
[Privacy Notice](#)